Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 162

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 8
Chunk 162
---
 awards under the 2017 Plan will remain outstanding in accordance with their respective terms. Under the 2020 Plan, there is an annual increase on January 1 of each year from January 1, 2021 continuing through January 1, 2030, by 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Board. On January 1, 2025, the Company increased the number of shares available for future grant under the 2020 Plan by 1,622,188 shares. The awards granted under the 2020 Plan typically vest over a two- to four-year period and have a 10-year contractual term. As of March 31, 2025, there was an aggregate of 4,869,232 shares of common stock issuable upon the exercise of outstanding options and 882,775 shares of common stock issuable upon the vesting of the outstanding RSU awards under the 2020 Plan. Additionally, there were an aggregate of 1,638,806 shares reserved for future issuance under the 2020 Plan, including shares forfeited from the 2017 Plan.Restricted Stock UnitsA summary of RSU award activity during the three months ended March 31, 2025 is as follows (in thousands except share and per share data):

12

Number of UnitsWeighted Average Grant-Date Fair ValueOutstanding RSU awards as of December 31, 2024— $— Granted898,175 10.56 Vested— — Forfeited(15,400)10.56 Outstanding RSU awards as of March 31, 2025882,775 $10.56 As of March 31, 2025, there was approximately $9.0 million of unrecognized stock-based compensation expense related to RSU awards that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 1.93 years. The aggregate fair value of RSU awards that vested during the three months ended March 31, 2025 and 2024 was zero and zero, respectively.Stock OptionsA summary of option activity during the three months ended March 31, 2025 is as follows (in thousands except share and per share data):NUMBER OF OPTIONSWEIGHTED-AVERAGE EXERCISE PRICEOutstanding as of December